CXCL10 and Familial prostate cancer: Furthermore, we show that blocking the CK2-NCoR network suppresses the in vivo tumorigenicity of prostate cancer cells via derepression of IP-10 mRNA, which may provide a potent therapeutic strategy for the treatment of prostate tumor progression.